Prednisone versus placebo in membranoproliferative glomerulonephritis: long-term clinicopathological correlations

Area of Science:

• Nephrology
• Pediatric Nephrology
• Immunopathology

Background:

• Primary membranoproliferative glomerulonephritis (MPGN) is a significant cause of kidney disease in children.
• Current treatment options for pediatric MPGN have varying efficacy and potential side effects.

Purpose of the Study:

• To evaluate the efficacy of prednisone in treating primary MPGN in children.
• To assess the impact of prednisone on disease progression, specifically end-stage renal disease (ESRD).

Main Methods:

• A double-blind, controlled study involving 18 children with primary MPGN.
• Patients were randomized to receive either prednisone or lactose (placebo).
• Renal biopsies and immunopathological studies were conducted at baseline, 3 years, and 5 years.

Main Results:

• None of the children treated with prednisone developed ESRD, compared to four in the control group.
• Remission rates were low in both groups (one in the prednisone group, two in the control group).
• Serial biopsies showed improvements in some immunopathological markers in both groups, but tubulointerstitial alterations and glomerulosclerosis increased generally, except in patients with proteinuria remission.

Conclusions:

• Prednisone therapy may potentially retard the progression to ESRD in children with primary MPGN.
• Further long-term studies with larger cohorts are required to definitively establish the utility of prednisone for MPGN in children.